PUMA protein in p53 regulatory molecule pattern determines the prognosis for patients with lymphoproliferative diseases.
The pool of apoptosis regulator proteins (p53, PUMA, p21, and MDM2) in the bone marrow, lymph node, and other tumor substrate cells were studied by immunocytochemical analysis in patients with chronic lymphoproliferative diseases. Two groups of patients were distinguished, with the disease course differing by activities of the studied molecules. Activity of p53 was the minimum in the group with benign course of the disease, and protein p21 was not detected; MDM2 protein was present in moderate amounts in the presence of high PUMA activity. High activities of p53, p21, and MDM2 and low PUMA activity were found in tumor cells of patients with malignant disease. These data can serve as a prognostic sign determining the aggressiveness of chronic lymphoproliferative disease course and for determining the strategy of chemotherapy and its correction.